Differences in Frequency of ERG Oncoprotein Expression Between Index Tumors of Caucasian and African American Patients With Prostate Cancer

doi:10.1016/j.urology.2012.07.001

Urology

Volume 80, Issue 4, October 2012, Pages 749-753

https://doi.org/10.1016/j.urology.2012.07.001 Get rights and content

Objective

To systematically evaluate the ETS-related gene (ERG) alterations in the multifocal tumor context using whole-mount prostatectomy specimens from African and Caucasian American patients matched for age, pathologic grade and stage. Oncogenic activation of the ERG is the most common early genomic alteration in patients with prostate cancer (CaP) in Western countries. However, ERG alterations have not been systematically examined in African American patients with a known greater risk of CaP incidence and mortality.

Methods

ERG oncoprotein expression was analyzed in 91 Caucasian and 91 African American patients with CaP, who were matched for age, Gleason score, and pathologic stage. A unique aspect of the present study was the evaluation of ERG in whole-mount prostatectomy sections, minimizing sampling bias and allowing the careful assessment of the ERG in the multifocal tumor context of CaP.

Results

The frequency of ERG-positive prostate tumors was significantly greater among Caucasian Americans than among African Americans when assessed in all tumor foci (41.9% vs 23.9%, P < .0001). A markedly greater frequency of ERG oncoprotein expression was noted between the index tumors of the Caucasian Americans (63.3%) and those of the African Americans (28.6%). Also, in the African American patients, the higher grade index tumors were predominantly ERG negative.

Conclusion

ERG typing of CaP established a major difference between the index tumors of Caucasian and African American patients. ERG-negative index tumors might indicate a less favorable outcome for African American patients. The results of the present study underscore that typing of CaP for the ERG could enhance our understanding of the biologic differences between the examined ethnic groups.

Section snippets

Material and Methods

Radical prostatectomy specimens were obtained from patients enrolled in the Center for Prostate Disease Research program and processed as whole mount specimens from 1996 to 2010 under an institutional review board-approved protocol from the Walter Reed National Military Medical Center. Archived specimens from the 1237 cases were examined with complete data on age at surgery (mean 59.5 ± 7.7 years, median 60.4, range 39.2-80.1), serum prostate-specific antigen level at diagnosis (mean 10.8 ±

Results

Overall, a greater frequency of ERG oncoprotein expression was detected in the CaP specimens of the Caucasian American patients than in those of the African American patients (Table 2). Of the 91 Caucasian American patients and 91 African American patients, 59 (65.9%) and 41 (42.9%) had ≥1 ERG-positive tumor, respectively (P = .0018). Moreover, 80 (41.9%) of the 191 individual tumor foci were ERG positive in the Caucasian Americans compared with 49 of 205 foci in the African Americans (23.9%; P

Comment

The results of the present study have underscored a striking difference in ERG oncoprotein expression between CaP of Caucasian and African American patients by a comprehensive evaluation of oncoprotein expression in multiple tumor foci of whole mount prostatectomy specimens from patients matched for age and tumor pathologic features. The differences in ERG expression between African Americans and Caucasian Americans with CaP are consistent with the data from our initial quantitative evaluations

Conclusions

The findings we have presented have the potential to stratify CaP by the status of cancer gene alterations, such as ERG, toward the understanding of widely observed differences of disease aggressiveness noted between African and Caucasian American patients.13, 14 The emerging ethnic differences in ERG alterations are intriguing. In a limited number of studies, much lower frequencies of ERG positivity have been reported in the CaP of Asian patients (∼20%).12, 15 Issues related to sampling bias,

Acknowledgment

To Dr. Ann W. Hsing, Cancer Prevention Institute of California, for valuable advice and Mr. Stephen Doyle, Center for Prostate Disease Research, for the artwork, with our sincere thanks.

References (15)

O.W. Brawley et al.
Prostate cancer and race
Curr Probl Cancer
(2007)
Y. Miyagi et al.
ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples
Mod Pathol
(2010)
A. Jemal et al.
Global cancer statistics
CA Cancer J Clin
(2011)
R. Siegel et al.
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths
CA Cancer J Clin
(2011)
S.J. Freedland et al.
Explaining racial differences in prostate cancer in the United States: sociology or biology?
Prostate
(2005)
G. Chornokur et al.
Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer
Prostate
(2011)
B. Han et al.
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer
Cancer Res
(2008)

There are more references available in the full text version of this article.

Cited by (66)

ETS factors in prostate cancer
2022, Cancer Letters
Citation Excerpt :
Initial reports of the high prevalence ETS fusions focused on cohorts that were predominantly comprised of Caucasian men. Several studies have shown that the prevalence of ERG fusions in African-American and Asian men is less than half (∼15–25% vs 40–60%) of that in Caucasian men [30,55–58]. These studies also show that PTEN loss, which is significantly associated with ERG fusions, is also much less common in non-Caucasian populations.
The ETS family of proteins consists of 28 transcription factors, many of which play critical roles in both normal tissue development and homeostasis and have been implicated in development and progression of a variety of cancers. In prostate cancer, gene fusion and overexpression of ETS factors ERG, FLI1, ETV1, ETV4 and ETV5 have been found in half of prostate cancer patients in Caucasian men and define the largest genetic subtype of prostate cancer. This review summarizes the data on the discovery, modeling, molecular taxonomy, lineage plasticity and therapeutic targeting of ETS family members in prostate cancer.
Prognostic features of Annexin A2 expression in prostate cancer
2021, Pathology
Citation Excerpt :
We found a significant association between ANXA2(+) status with higher grade groups and advanced pathological stages among CA patients and in the combined study cohort. While ANXA2 expression status was not associated with race, the inverse association between ANXA2 and ERG expression, and the higher prevalence of ERG(+) tumours among CA men corroborated published reports.3,4,8,10,11,27 The higher prevalence of ANXA2(–)/ERG(+) tumours among CA men, and of ANXA2(+)/ERG(–) tumours among AA men further reflects the interaction between ANXA2 and ERG.
ANXA2 (Annexin A2 or Annexin II) is a calcium dependent phospholipid binding protein with diverse cellular functions. While ANXA2 is either absent or expressed focally in the prostate epithelium of well and moderately differentiated tumours, it is highly expressed in a subset of poorly differentiated tumours. Here we examined the association between ANXA2 expression and tumour progression, with consideration of ERG expression status and patient race (Caucasian American and African American).
We evaluated ANXA2 and ERG expression in index tumours by immunohistochemistry of whole mounted prostate sections and tissue microarrays derived from radical prostatectomies of 176 patients, matched for long term post-radical prostatectomy follow-up of up to 22 years (median 12.6 years), race and pathological stage. Expression of ERG and ANXA2 was analysed for correlation with grade group (GG), and pathological T (pT) stage. Kaplan–Meier estimation curves were used to examine associations between ANXA2 or ERG expression and biochemical recurrence (BCR) free survival, and distant metastasis free survival.
Significant associations were found between ANXA2(+) index tumours and poorest grade groups (GG 4–5, p=0.0037), and worse pathological stage (pT 3–4, p=0.0142). Patients with ANXA2(+) prostate tumours showed trends towards earlier BCR and metastatic progression. ANXA2(+)/ERG(–) tumours were found to be associated with GG 4–5; ANXA2(–)/ERG(+) tumours, with GG 1–2 (p=0.0036). ANXA2 expression was not associated with patient race.
The association between high ANXA2 expression and prostate tumours of higher grade (GG 4–5) and stage (pT 3–4) suggests a potential use for ANXA2 as a prognostic biomarker of aggressive prostate cancer.
A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men
2020, Urology
To validate the 17-gene Oncotype DX Genomic Prostate Score (GPS) as a predictor of adverse pathology (AP) in African American (AA) men and to assess the distribution of GPS in AA and European American (EA) men with localized prostate cancer.
The study populations were derived from 2 multi-institutional observational studies. Between February 2009 and September 2014, AA and EA men who elected immediate radical prostatectomy after a ≥10-core transrectal ultrasound biopsy were included in the study. Logistic regressions, area under the receiver operating characteristics curves (AUC), calibration curves, and predictive values were used to compare the accuracy of GPS. AP was defined as primary Gleason grade 4, presence of any Gleason pattern 5, and/or non-organ-confined disease (≥pT3aN0M0) at radical prostatectomy.
Overall, 96 AA and 76 EA men were selected and 46 (26.7%) had AP. GPS result was a significant predictor of AP (odds ratio per 20 GPS units [OR/20 units] in AA: 4.58; 95% confidence interval (CI) 1.8-11.5, P = .001; and EA: 4.88; 95% CI 1.8-13.5, P = .002). On multivariate analysis, there was no significant interaction between GPS and race (P >.10). GPS remained significant in models adjusted for either National Comprehensive Cancer Network (NCCN) risk group or Cancer of the Prostate Risk Assessment (CAPRA) score. In race-stratified models, area under the receiver operating characteristics curves for GPS/20 units was 0.69 for AAs vs 0.74 for EAs (P = .79). The GPS distributions were not statistically different by race (all P >.05).
In this clinical validation study, the Oncotype DX GPS is an independent predictor of AP at prostatectomy in AA and EA men with similar predictive accuracy and distributions.
Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort
2018, European Urology Focus
ETS-related gene (ERG) oncogenic activation is the most common genomic alteration in prostate cancer (CaP) although it occurs less frequently in African American (AA) versus Caucasian (CA) patients, and the potential role of ERG as a prognostic marker has not been confirmed.
This study was conducted to confirm strong racial variation in the prevalence of ERG oncoprotein expression and to examine ERG oncoprotein expression, race, and body mass index as independent and joint predictors of CaP biochemical recurrence (BCR) following radical prostatectomy (RP).
A retrospective cohort study of CA and AA CaP patients enrolled at Walter Reed National Military Medical Center, who donated clinically annotated, whole-mounted, prostatectomy specimens between 1994 and 2014 following RP, was conducted.
Kaplan–Meier (KM) estimation curves and multivariable Cox proportional hazards models were used to examine time to BCR as a function of ERG status, patient race, and obesity.
Among 930 eligible patients (36.1% AA and 63.9% CA), with 155 (16.7%) BCR events and a median follow-up time of 5.1 yr, ERG oncoprotein expression was significantly less prevalent in index tumors of AA versus CA patients (23.2% vs 49.3%; p < 0.0001). KM curves showed significantly poorer BCR-free survival for CA patients with ERG-negative index tumors but not for AA patients. Race-stratified multivariable analyses revealed a significant association between ERG-negative index tumors and poorer BCR-free survival among CA patients (hazards ratio = 1.67, confidence interval = 1.07, 2.61; p = 0.024). Less heterogeneity in ERG expression among AA patients may reduce the ability to show its association with BCR.
Striking racial variation in ERG oncoprotein expression was confirmed. A novel observation was the importance of index tumor ERG-negative status in predicting CaP progression for CA patients.
ETS-related gene (ERG) typing of tumors may be useful in prognosticating prostate cancer aggressiveness.
Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy
2016, Journal of Urology
Citation Excerpt :
Similar to any cancer, the addition of T2:ERG to the baseline model did not improve the detection of high grade PCa over the baseline model for AA men or the overall cohort. The data on the prognostic value of T2:ERG in largely nonAA cohorts remain conflicting20–24 but this cohort suggests that there is little association for AA men. As in most studies, patients were self-identified as AA.10
Prostate specific antigen has decreased performance characteristics for the detection of prostate cancer in African-American men. We evaluated urinary PCA3 and TMPRSS2:ERG in a racially diverse group of men.
After institutional review board approval, post-examination urine was prospectively collected before prostate biopsy. PCA3 and TMPRSS2:ERG RNA copies were quantified using transcription mediated amplification assays (Hologic, San Diego, California). Prediction models were created using standard of care variables (age, race, family history, prior biopsy, abnormal digital rectal examination) plus prostate specific antigen. Decision curve analysis was performed to compare the net benefit of PCA3 and TMPRSS2:ERG.
Of 304 patients 182 (60%) were African-American and 139 (46%) were diagnosed with prostate cancer (69% African-American). PCA3 and TMPRSS2:ERG scores were greater in men with prostate cancer, 3 or more cores, 33.3% or more cores, greater than 50% involvement of greatest biopsy core and Epstein significant prostate cancer (p <0.01). PCA3 added to the standard of care plus prostate specific antigen model for the detection of any prostate cancer in the overall cohort (0.747 vs 0.677, p <0.0001) in African-American men only (0.711 vs 0.638, p=0.0002) and nonAfrican-American men (0.781 vs 0.732, p=0.0016). PCA3 added to the model for the prediction of high grade prostate cancer for the overall cohort (0.804 vs 0.78, p=0.0002) and African-American men only (0.759 vs 0.717, p=0.0003) but not nonAfrican-American men. Decision curve analysis demonstrated improvement with the addition of PCA3. For African-American men TMPRSS2:ERG did not improve concordance statistics for the detection of prostate cancer.
For African-American men urinary PCA3 improves the ability to predict the presence of any and high grade prostate cancer. However, the TMPRSS2:ERG urinary assay does not add significantly to standard tools.
Racial Disparities in Prostate Cancer Mortality in the 50 Largest US Cities
2016, Cancer Epidemiology
This paper presents race-specific prostate cancer mortality rates and the corresponding disparities for the largest cities in the US over two decades.
The 50 largest cities in the US were the units of analysis. Data from two 5-year periods were analyzed: 1990–1994 and 2005–2009. Numerator data were abstracted from national death files where the cause was malignant neoplasm of prostate (prostate cancer) (ICD9 = 185 and ICD10 = C61). Population-based denominators were obtained from US Census data. To measure the racial disparity, we calculated non-Hispanic Black: non-Hispanic White rate ratios (RRs), rate differences (RDs), and corresponding confidence intervals for each 5-year period. We also calculated correlation and unadjusted regression coefficients for 11 city-level variables, such as segregation and median income, and the RDs.
At the final time point (2005–2009), the US and all 41 cities included in the analyses had a RR greater than 1 (indicating that the Black rate was higher than the White rate) (range = 1.13 in Minneapolis to 3.24 in Los Angeles), 37 of them statistically significantly so. The US and 26 of the 41 cities saw an increase in the Black:White RR between the time points. The level of disparity within a city was associated with the degree of Black segregation.
This analysis revealed large disparities in Black:White prostate cancer mortality in the US and many of its largest cities over the past two decades. The data show considerable variation in the degree of disparity across cities, even among cities within the same state. This type of specific city-level data can be used to motivate public health professionals, government officials, cancer control agencies, and community-based organizations in cities with large or increasing disparities to demand more resources, focus research efforts, and implement effective policy and programmatic changes in order to combat this highly prevalent condition.

View all citing articles on Scopus

: Equal contribution: Philip Rosen and David Pfister

: Financial Disclosure: The views expressed in this report are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense, or the U.S. Government.

: Funding Support: This research was supported by the National Cancer Institute R01CA162383 grant to S. Srivastava.

View full text

Rapid CommunicationDifferences in Frequency of ERG Oncoprotein Expression Between Index Tumors of Caucasian and African American Patients With Prostate Cancer

Objective

Methods

Results

Conclusion

Section snippets

Material and Methods

Results

Comment

Conclusions

Acknowledgment

Curr Probl Cancer

Mod Pathol

Global cancer statistics

CA Cancer J Clin

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

CA Cancer J Clin

Explaining racial differences in prostate cancer in the United States: sociology or biology?

Prostate

Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer

Prostate

A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer

Cancer Res

Rapid Communication
Differences in Frequency of ERG Oncoprotein Expression Between Index Tumors of Caucasian and African American Patients With Prostate Cancer